Identification
NameDolutegravir
Accession NumberDB08930
TypeSmall Molecule
GroupsApproved
Description

Dolutegravir is indicated for HIV-1 infection for adults and children and adolescents ≥12 years of age and weighing ≥40 kg. It is marketed as Tivicay as dolutegravir sodium. 52.6 mg of dolutegravir sodium is equivalent to 50 mg dolutegravir free acid. FDA approved on August 12, 2013.

Structure
Thumb
SynonymsNot Available
External IDs GSK572 / S-349572 / S/GSK1349572
Product Ingredients
IngredientUNIICASInChI KeyDetails
Dolutegravir Sodium1Q1V9V5WYQ 1051375-19-9UGWJRRXTMKRYNK-VSLILLSYSA-MDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TivicayTablet50 mgOralViiv Healthcare Ulc2013-11-08Not applicableCanada
TivicayTablet10 mgOralViiv Healthcare Ulc2017-06-20Not applicableCanada
TivicayTablet, film coated50 mg/1OralViiv Healthcare Ulc2013-08-13Not applicableUs49702 0228 13 nlmimage10 d23d694b
TivicayTablet, film coated50 mg/1OralA S Medication Solutions2013-08-132017-06-20Us
TivicayTablet, film coated50 mgOralViiv Healthcare Ulc2014-01-16Not applicableEu
TivicayTablet25 mgOralViiv Healthcare Ulc2017-06-20Not applicableCanada
TivicayTablet, film coated10 mg/1OralViiv Healthcare Ulc2016-06-09Not applicableUs
TivicayTablet, film coated50 mg/1OralRemedy Repack2016-07-11Not applicableUs
TivicayTablet, film coated50 mgOralViiv Healthcare Ulc2014-01-16Not applicableEu
TivicayTablet, film coated25 mg/1OralViiv Healthcare Ulc2016-06-09Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
TriumeqViiv Healthcare Ulc
Categories
UNIIDKO1W9H7M1
CAS number1051375-16-6
WeightAverage: 419.3788
Monoisotopic: 419.129277143
Chemical FormulaC20H19F2N3O5
InChI KeyRHWKPHLQXYSBKR-BMIGLBTASA-N
InChI
InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
IUPAC Name
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.0³,⁸]tetradeca-10,13-diene-13-carboxamide
SMILES
[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[[email protected]](C)CCO2
Pharmacology
Indication

Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children aged 12 years and older and weighing at least 40 kg.

Structured Indications
Pharmacodynamics

HIV-1 infected subjects on dolutegravir monotherapy demonstrated rapid and dose-dependent antiviral activity with mean declines from baseline to Day 11 in HIV-1 RNA of 1.5, 2.0, and 2.5 log10 for dolutegravir 2 mg, 10 mg, and 50 mg once daily, respectively. Antiviral response was maintained for 3 to 4 days after the last 50 mg dose. Dolutegravir did not prolong the QTc interval over 24 hours postdose. The maximum mean QTc change based on Fridericia correction method (QTcF) for dolutegravir was 2.4 msec (1-sided 95% upper CI: 4.9 msec). Those given a 50 mg once daily dose of dolutegravir also experienced a decrease in creatinine clearance as determined by 24-hour urine collection after 14 days. There is no significant effect on actual glomerular filtration rate or renal plasma flow compared to placebo.

Mechanism of action

Dolutegravir is an HIV-1 antiviral agent. It inhibits HIV integrase by binding to the active site and blocking the strand transfer step to retroviral DNA integration. This is an essential step of the HIV replication cycle and will result in an inhibition of viral activity. Dolutegravir has a mean EC50 value of 0.5 nM (0.21 ng/mL) to 2.1 nM (0.85 ng/mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells.

TargetKindPharmacological actionActionsOrganismUniProt ID
IntegraseProteinyes
inhibitor
Human immunodeficiency virus 1Q7ZJM1 details
Related Articles
Absorption

When 50 mg of dolutegravir once daily was orally administered to HIV-1 infected adults, the AUC (0-24), Cmax, and Cmin is 53.6 mcg.h/mL, 3.67 mcg/mL, and 1.11 mcg/mL, respectively. The peak plasma concentration was observed 2 to 3 hours post dose. Steady state is achieved within approximately 5 days with average accumulation ratios for AUC, Cmax, and C24h ranging from 1.2 to 1.5. When 50 mg once daily is given to pediatric patients (12 to <18 years and weighing ≥40 kg) the Cmax, AUC (0-24), and C24 is 3.49 mcg/mL, 46 mcg.h/mL, and 0.90 mcg/mL respectively.

Volume of distribution

Volume of distribution (Vd/F), 50 mg once daily = 17.4 L. The median dolutegravir concentration in the CSF was 18 ng/mL after 2 weeks of treatment.

Protein binding

Dolutegravir is highly protein bound (≥98.9%) to human plasma proteins.

Metabolism

Dolutegravir is primarily metabolized by UGT1A1 with some minor contributed CYP3A.

Route of elimination

When a single oral dose of dolutegravir is given, 53% was excreted unchanged in the feces. 31% is excreted in urine in which consists of the ether glucuronide of dolutegravir (18.9%), a metabolite formed by oxidation at the benzylic carbon (3.0%), and its hydrolytic N-dealkylation product (3.6%). Renal elimination of unchanged drug was low (<1%).

Half life

Terminal half life = 14 hours

Clearance

Apparent clearance (CL/F) = 1.0 L/h

Toxicity

The most common adverse reactions of moderate to severe intensity and incidence ≥2% (in those receiving TIVICAY in any one adult trial) are insomnia and headache.

Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
UDP-glucuronosyltransferase 1-1UGT1A1*28 or UGT1A 7/7Not Availableextra TA in promoter Effect Directly StudiedPoor drug metabolizer. Details
UDP-glucuronosyltransferase 1-1UGT1A1*6Not AvailableG > A Effect Directly StudiedPoor drug metabolizer. Details
UDP-glucuronosyltransferase 1-1UGT1A1*37Not AvailableTA pair insertion Effect Directly StudiedPoor drug metabolizer. Details
Interactions
Drug Interactions
DrugInteractionDrug group
Aluminum hydroxideThe serum concentration of Dolutegravir can be decreased when it is combined with Aluminum hydroxide.Approved
CalciumThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium.Nutraceutical
Calcium AcetateThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Acetate.Approved
Calcium CarbonateThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium carbonate.Approved
Calcium ChlorideThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium citrate.Approved
Calcium glubionateThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
CarbamazepineThe serum concentration of Dolutegravir can be decreased when it is combined with Carbamazepine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Dolutegravir.Approved
EfavirenzThe serum concentration of Dolutegravir can be decreased when it is combined with Efavirenz.Approved, Investigational
EtravirineThe serum concentration of Dolutegravir can be decreased when it is combined with Etravirine.Approved
Ferric CarboxymaltoseThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Dolutegravir can be decreased when it is combined with Ferric pyrophosphate.Approved
FosamprenavirThe serum concentration of Dolutegravir can be decreased when it is combined with Fosamprenavir.Approved
FosphenytoinThe serum concentration of Dolutegravir can be decreased when it is combined with Fosphenytoin.Approved
IronThe serum concentration of Dolutegravir can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Dolutegravir can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Dolutegravir can be decreased when it is combined with Iron saccharate.Approved
Magnesium HydroxideThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
MetforminThe serum concentration of Metformin can be increased when it is combined with Dolutegravir.Approved
NevirapineThe serum concentration of Dolutegravir can be decreased when it is combined with Nevirapine.Approved
OxcarbazepineThe serum concentration of Dolutegravir can be decreased when it is combined with Oxcarbazepine.Approved
PhenobarbitalThe serum concentration of Dolutegravir can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Dolutegravir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PrimidoneThe serum concentration of Dolutegravir can be decreased when it is combined with Primidone.Approved, Vet Approved
RifampicinThe serum concentration of Dolutegravir can be decreased when it is combined with Rifampicin.Approved
SeleniumThe serum concentration of Dolutegravir can be decreased when it is combined with Selenium.Approved, Vet Approved
St. John's WortThe serum concentration of Dolutegravir can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
SucralfateThe serum concentration of Dolutegravir can be decreased when it is combined with Sucralfate.Approved
TipranavirThe serum concentration of Dolutegravir can be decreased when it is combined with Tipranavir.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC: Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010 Jan;54(1):254-8. doi: 10.1128/AAC.00842-09. Epub 2009 Nov 2. [PubMed:19884365 ]
  2. Lenz JC, Rockstroh JK: S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin Investig Drugs. 2011 Apr;20(4):537-48. doi: 10.1517/13543784.2011.562189. Epub 2011 Mar 8. [PubMed:21381981 ]
  3. Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, Stroder R, Chen S, Underwood M, Fujiwara T, Piscitelli S, Lalezari J: Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011 Sep 10;25(14):1737-45. doi: 10.1097/QAD.0b013e32834a1dd9. [PubMed:21716073 ]
  4. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P: Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. doi: 10.1124/mol.111.073189. Epub 2011 Jun 30. [PubMed:21719464 ]
  5. Katlama C, Murphy R: Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012 Apr;21(4):523-30. doi: 10.1517/13543784.2012.661713. Epub 2012 Mar 2. [PubMed:22380682 ]
  6. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S: Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. [PubMed:23830355 ]
  7. Authors unspecified: Dolutegravir (Tivicay) for HIV. Med Lett Drugs Ther. 2013 Sep 30;55(1426):77-9. [PubMed:24081387 ]
  8. Cottrell ML, Hadzic T, Kashuba AD: Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013 Nov;52(11):981-94. doi: 10.1007/s40262-013-0093-2. [PubMed:23824675 ]
  9. Ballantyne AD, Perry CM: Dolutegravir: first global approval. Drugs. 2013 Sep;73(14):1627-37. doi: 10.1007/s40265-013-0121-4. [PubMed:24052331 ]
  10. Boyd MA, Donovan B: Antiretroviral therapy: dolutegravir sets SAIL(ING). Lancet. 2013 Aug 24;382(9893):664-6. doi: 10.1016/S0140-6736(13)61456-7. Epub 2013 Jul 3. [PubMed:23830358 ]
External Links
ATC CodesJ05AR13 — Lamivudine, abacavir and dolutegravirJ05AX12 — Dolutegravir
AHFS Codes
  • 8:18.08.12
PDB EntriesNot Available
FDA labelDownload (332 KB)
MSDSDownload (61.6 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHIV Disease2
1CompletedNot AvailableHIV Disease / Human Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHIV-DDI1
1CompletedNot AvailableHIV-infection/AIDS1
1CompletedNot AvailableHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
1CompletedNot AvailableInfections, Human Immunodeficiency Virus and Hepatitis2
1CompletedNot AvailableInfections, Human Immunodeficiency Virus and Herpesviridae1
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections2
1CompletedOtherHuman Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionHealthy Adult Females1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1Not Yet RecruitingTreatmentHIV Disease1
1Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2Active Not RecruitingTreatmentDolutegravir / Human Immunodeficiency Virus (HIV) / Monotherapy / Treatment Efficacy1
2Active Not RecruitingTreatmentHIV-1 Infections2
2Active Not RecruitingTreatmentHIV/AIDS / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHIV-1 Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingTreatmentDolutegravir / Monotherapy / Primary HIV Infection / Treatment Efficacy1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2TerminatedTreatmentHIV-1 Infections1
2, 3RecruitingTreatmentHIV Disease / Pregnancy1
2, 3WithdrawnTreatmentHIV/AIDS1
3Active Not RecruitingTreatmentHIV-1 Infections2
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections4
3CompletedTreatmentHIV-1 Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3CompletedTreatmentInfection, Human Immunodeficiency Virus I1
3No Longer AvailableNot AvailableHuman Immunodeficiency Virus (HIV)1
3Not Yet RecruitingTreatmentHIV Infection Primary1
3Not Yet RecruitingTreatmentHIV-1 Infections1
3Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3RecruitingTreatmentAcute HIV Infection1
3RecruitingTreatmentHIV Disease1
3RecruitingTreatmentHIV-1 Infections2
3RecruitingTreatmentHIV-1-infection1
3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3Unknown StatusTreatmentInfection, Human Immunodeficiency Virus I1
4Active Not RecruitingTreatmentHIV Disease3
4Active Not RecruitingTreatmentHIV-1 Infections1
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
4CompletedBasic ScienceHIV Disease1
4CompletedPreventionHuman Immunodeficiency Virus (HIV)1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
4Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
4Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingOtherHIV/AIDS1
4RecruitingTreatmentAcquired Immune Deficiency Syndrome Virus1
4RecruitingTreatmentHIV Disease1
4RecruitingTreatmentHIV-1 Infections1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections2
4Unknown StatusTreatmentHIV Disease1
Not AvailableActive Not RecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableActive Not RecruitingTreatmentChronic Infection / HIV Disease1
Not AvailableCompletedNot AvailableChronic Hepatitis C Infection / HIV Disease1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingNot AvailableMinor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed1
Not AvailableRecruitingBasic ScienceHIV Disease1
Not AvailableRecruitingTreatmentAcute HIV Infection / HIV Disease1
Not AvailableRecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg
Tablet, film coatedOral50 mg/1
TabletOral
Tablet, film coatedOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5905082 Yes1996-11-182016-11-18Us
US6294540 Yes1998-11-142018-11-14Us
US6417191 Yes1996-09-282016-09-28Us
US8129385 No2007-10-052027-10-05Us
US9242986 No2009-10-082029-10-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleFDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0922 mg/mLALOGPS
logP0.98ALOGPS
logP1.1ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)8.7ChemAxon
pKa (Strongest Basic)0.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.77 m3·mol-1ChemAxon
Polarizability39.99 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassPyridines and derivatives
Direct ParentPyridinecarboxylic acids and derivatives
Alternative Parents2-heteroaryl carboxamides / Fluorobenzenes / Hydroxypyridines / 1,3-oxazinanes / Aryl fluorides / Vinylogous amides / Vinylogous acids / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides
SubstituentsPyridine carboxylic acid or derivatives / 2-heteroaryl carboxamide / Hydroxypyridine / Fluorobenzene / Halobenzene / 1,3-oxazinane / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Oxazinane
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsorganofluorine compound, monocarboxylic acid amide, organic heterotricyclic compound (CHEBI:76010 )

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q7ZJM1
Molecular Weight:
32226.645 Da
References
  1. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P: Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. doi: 10.1124/mol.111.073189. Epub 2011 Jun 30. [PubMed:21719464 ]
  2. Waki K, Sugawara Y: Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends. 2011;5(5):189-91. [PubMed:22101373 ]
  3. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T: The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301. doi: 10.1097/QAI.0b013e31826bfd02. [PubMed:22878423 ]
  4. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C: Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21-7. doi: 10.1097/QAI.0b013e318276cda9. [PubMed:23075918 ]
  5. Cottrell ML, Hadzic T, Kashuba AD: Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013 Nov;52(11):981-94. doi: 10.1007/s40262-013-0093-2. [PubMed:23824675 ]
  6. Rathbun RC, Lockhart SM, Miller MM, Liedtke MD: Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Ann Pharmacother. 2014 Mar;48(3):395-403. doi: 10.1177/1060028013513558. Epub 2013 Nov 19. [PubMed:24259658 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3'). Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression. Modulates transcription transactivation by NR3C1, AR and PGR. Isoform 5 activates the U2 small nuclear RNA (snRNA) promoter.
Gene Name:
POU2F2
Uniprot ID:
P09086
Molecular Weight:
51208.51 Da
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).
Components:
NameUniProt IDDetails
Cytochrome P450 3A4P08684 Details
Cytochrome P450 3A43Q9HB55 Details
Cytochrome P450 3A5P20815 Details
Cytochrome P450 3A7P24462 Details
Drug created on November 11, 2013 14:17 / Updated on July 22, 2017 18:10